Management ChangeApr 22, 2026, 04:32 PM
Barinthus Biotherapeutics Appoints Douglas Swirsky as New CFO
AI Summary
Barinthus Biotherapeutics plc. announced the appointment of Douglas Swirsky as its new Chief Financial Officer and principal accounting officer. The appointment is effective May 1, 2026. Mr. Swirsky has over 25 years of experience, including prior roles as CFO of MaxCyte, Inc. and AavantiBio, Inc., and as President and CEO of Rexahn Pharmaceuticals, Inc. He also serves as chairman of the board for Cellectar Biosciences, Inc.
Key Highlights
- Douglas Swirsky appointed Chief Financial Officer and principal accounting officer.
- Appointment is effective as of May 1, 2026.
- Mr. Swirsky brings over 25 years of experience.
- He previously served as CFO of MaxCyte, Inc. and AavantiBio, Inc.
- Currently serves as chairman of Cellectar Biosciences, Inc. board.
Price Impact
More from BRNS